BioTech

Immune Design Corp (NASDAQ:IMDZ) Bounces off Lows

Immune Design Corp (NASDAQ:IMDZ)

Immune Design Corp (NASDAQ:IMDZ)

Shares of Immune Design Corp (NASDAQ:IMDZ) gained 12.2% ahead of their much-awaited financial results for the third quarter, ended September 30, 2017. The clinical stage immunotherapy company will release the results on November 1, 2017, after the close of the U.S. markets.

Immune Design Corp (NASDAQ:IMDZ)

Earnings Expectations

Investor confidence in the stock has taken a hit this month as seen by the stock shedding more than 50% in its market value. The stock has come under pressure following the pricing of an underwritten public offering of 19.5 million shares at a price of $4.10 a share. Investors pushed the stock lower after the company offered the shares at a discount to the market price.

Last quarter, the immunotherapy company reported a positive earnings surprise of 16.92% outpacing the consensus estimates of average earnings beat of 12.94%. A similar performance with Q3 financial results could result in the stock bouncing back from current trading levels.

Increased implied volatility on Immune Design Corp (NASDAQ:IMDZ) November options is already fuelling suggestions of a potential big move in either direction. Analysts at Zack’s research currently rate the stock as a ‘hold’.

Immune Design Pipeline

Progress on the company’s pipeline candidates should have an impact on the stock’s direction of trade going forward. The company’s lead candidate drugs are CMB305 for the treatment of solid tumor and G100 for the treatment of merkel cell carcinoma.

Immune Design is evaluating CMB305 both as a monotherapy and in combination with Roche Holding Ltd. (ADR)(OTCMKTS:RHHBY) Tecentriq. G100 is being developed on the GLAAS platform in collaboration with Merck for the treatment of patients with non-Hodgkin’s lymphoma (NHL).

The European Medicine Agency has granted G100 Orphan Drug Designation for the treatment of NHL. The designation is expected to accelerate its development while also guaranteeing market exclusivity for up to 10 years.

Immune Design Corp (NASDAQ:IMDZ) has the financial power to accelerate the development of the two candidate drugs given the pricing of the $80 million public offering.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $IMDZ and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Monica has an undergraduate degree in Accounting and an MBA she earned – with Honors. She has six years of experience in the financial markets and has been an analyst for the past two years.

Previous ArticleNext Article
Monica has an undergraduate degree in Accounting and an MBA she earned - with Honors. She has six years of experience in the financial markets and has been an analyst for the past two years.

Leave a Reply

Your email address will not be published. Required fields are marked *